A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(37 sites)

United States

First Physicians Group /ID# 272180, Sarasota, Florida

St. Elizabeth Medical Center - Edgewood /ID# 272113, Edgewood, Kentucky

Baptist Health Lexington /ID# 272211, Lexington, Kentucky

UMass Memorial Medical Center /ID# 272122, Worcester, Massachusetts

Karmanos Cancer Institute - Detroit /ID# 272112, Detroit, Michigan

Allegheny Health Network West Penn Hospital /ID# 272267, Pittsburgh, Pennsylvania

Australia

Blacktown Hospital /ID# 272182, Blacktown, New South Wales

Newcastle Private Hosptial /ID# 272213, Lambton Heights, New South Wales

Royal Brisbane and Women's Hospital /ID# 272123, Brisbane, Queensland

Icon Cancer Centre Chermside /ID# 272220, Chermside, Queensland

Ballarat Base Hospital /ID# 272240, Ballarat, Victoria